# **Scientific Poster Presentations, I**

## Monday, October 13

Convention Center: Exhibit Hall 5 11:30 a.m.–1:15 p.m.

### **ENCORE PRESENTATIONS**

Abstracts marked with an "E" are Encore Presentations. Encore Presentations undergo the same peer-review process as all other presentations, but they may have been presented elsewhere or published in abstract form before the 2014 Annual Meeting.

#### **AWARDS COMPETITION**

Abstracts marked with an "F" are finalists for the Best Student Poster, Best Resident and Fellow Poster, and Best Paper awards. These papers were selected by special panels of reviewers. Award winners for the Best Student Poster and Best Resident and Fellow Poster will be announced at 1:00 p.m. on Monday, October 13, in the Austin Convention Center, Exhibit Hall 5. The award winner for the Best Paper will be announced at 9:45 a.m. on Tuesday, October 14, in Exhibit Hall 5.

#### **ORIGINAL RESEARCH**

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

### **Adult Medicine**

4E. Lorcaserin free plasma levels at recommended dose are sufficient to activate 5-HT<sub>2C</sub> but not <sub>2A</sub> or <sub>2B</sub> receptors.

*Eric Ravussin, PhD*<sup>1</sup>, Yuhan Li, PhD<sup>2</sup>, David Unett, PhD<sup>3</sup>, Michael Morgan, PhD<sup>3</sup>, William Shanahan, MD<sup>3</sup>, William Soliman, PhD<sup>2</sup>; (1)Pennington Biomedical Research Center; (2)Eisai Inc.; (3)Arena Pharmaceuticals

# **Ambulatory Care**

11F. Physician Engagement and Acceptance of Collaborative Treatment of Hypertension in Primary Care. *Steven Smith, PharmD, MPH*<sup>1</sup>, Michaela Hasan, PharmD<sup>2</sup>, Amy Huebschmann, MD<sup>3</sup>, Richard Penaloza, MD<sup>3</sup>, Wagner Schorr-Ratzlaff, MD<sup>3</sup>, Amber Sieja, MD<sup>3</sup>, Katy E. Trinkley, PharmD<sup>2</sup>; (1)Department of Pharmacotherapy & Translational Research; Department of Community Health & Family Medicine, University of Florida, Gainesville, FL; (2)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO; (3)Division of Internal Medicine, Department of Medicine, University of Colorado, Aurora, CO

14E. Physician-pharmacist collaborative management of asthma in primary care. *Dr. Tyler Gums, Pharm.D.*<sup>1</sup>, Dr. Barry Carter, Pharm.D.<sup>2</sup>, Dr. Gary Malivetz, Pharm.D.<sup>3</sup>, Dr. Lucinda Buys, Pharm.D.<sup>4</sup>, Dr. Kurt Rosenkrans, M.D.<sup>5</sup>, Ms. Liz Uribe, M.S.<sup>6</sup>, Dr. Christopher Coffey, Ph.D.<sup>7</sup>, Eric MacLaughlin, Pharm.D.<sup>8</sup>, Rodney B. Young, M.D.<sup>9</sup>, Dr. Adrienne Ables, Pharm.D.<sup>10</sup>, Nima Patel-Shori, PharmD, BCACP<sup>11</sup>, Dr. Angela Bosinski, Pharm.D.<sup>12</sup>; (1)University of Iowa, Iowa City, IA; (2)University of

Iowa College of Pharmacy, Iowa City, IA; (3)Division of Pharmaceutics and Translational Therapeutics, University of Iowa, IA; (4)Siouxland Medical Education Foundation, Inc., Sioux City, IA; (5)Mercy Sioux City, IA; (6)Department of Biostatistics; (7)University of Iowa-Department of Biostatistics, Iowa City, IA; (8)Department of Pharmacy Practice, Texas Tech University Health Sciences Center, Amarillo, TX; (9)Texas Tech University Health Sciences Center School of Medicine, Amarillo, TX; (10)Edward Via College of Osteopathic Medicine; (11)Temple University School of Pharmacy, Philadelphia, PA; (12)University of Buffalo

#### Cardiovascular

- 17. Aspirin pharmacodynamics are improved in obesity patients following bariatric surgery. *Dr. Nicholas B. Norgard, Pharm.D.*<sup>1</sup>, Dr. Scott Monte, Pharm.D.<sup>2</sup>, Dr. Stanley Fernandez, MD<sup>3</sup>; (1)Department of Pharmacy Practice, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY; (2)Department of Pharmacy Practice, University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY; (3)Division of Cardiovascular Medicine, University at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY
- 19. Exacerbations of congestive cardiac failure are associated with elevated INRs in patients on warfarin. Mr. Greg Roberts, BPharm, FSHP, Ms. Michaela Delcampo, BPharm (hons), MClinPharm; Pharmacy Department, Flinders Medical Centre, Bedford Park, Australia
- 28. An evaluation of factors associated with QTc-Interval prolongation in patients receiving propofol. *Dr. Michael Scalese, Pharm.D., BCPS*<sup>1</sup>, Dr. Holly Herring, Pharm.D., BCPS<sup>1</sup>, R. Chris Rathbun, Pharm.D., BCPS<sup>2</sup>, Dr. Grant Skrepnek, Ph.D., Rph<sup>1</sup>, Dr. Toni Ripley, Pharm.D., FCCP, BCPS<sup>1</sup>; (1)The University of Oklahoma College of Pharmacy, Oklahoma City, OK; (2)Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 30. Incidence and risk factor analysis for alterations in hemostasis in mechanical circulatory support recipients.
- *Dr. Alex Lopilato, PharmD*<sup>1</sup>, Christina T. Doligalski, PharmD, BCPS<sup>1</sup>, Dr. Christiano Caldeira, MD<sup>2</sup>; (1)Department of Pharmacy, Tampa General Hospital, Tampa, FL; (2)Florida Advanced Cardiothoracic Surgery, Tampa General Hospital, Tampa, FL
- 31. Effect of intravenous post-operative anticoagulation on thrombotic and bleeding complications after implantation of a Jarvik 2000 left ventricular assist device.
- *Jenna Siskey, PharmD*<sup>1</sup>, Ian Hollis, PharmD<sup>1</sup>, Brett Sheridan, MD<sup>2</sup>; (1)Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; (2)Division of Cardiothoracic Surgery, University of North Carolina Medical Center, Chapel Hill, NC
- 32. Initial characterization of cytochrome P450-derived eicosanoids as a predictive biomarker in coronary artery disease.
- Akinyemi Oni-Orisan, Pharm.D.<sup>1</sup>, Katherine N. Theken, Pharm.D., Ph.D.<sup>1</sup>, Robert N. Schuck, Pharm.D., Ph.D.<sup>1</sup>, Matthew L. Edin, Ph.D.<sup>2</sup>, Alan L. Hinderliter, M.D.<sup>3</sup>, George A. Stouffer, M.D.<sup>3</sup>, Darryl C. Zeldin, M.D.<sup>2</sup>, Craig R. Lee, Pharm.D., Ph.D., FCCP<sup>1</sup>; (1)Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC; (2)Environmental Cardiopulmonary Disease Group, National Institute of Environmental Health Sciences, Research Triangle Park, NC; (3)Division of Cardiology, UNC School of Medicine, Chapel Hill, NC

#### **Clinical Administration**

35. Development and initial validation of the Academic Health Center Pharmacists' Activity Index. *Brandon Patterson, PharmD, PhD*, Laura Siemianowski, PharmD, BCPS, Sanchita Sen, PharmD, BCPS; Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, Philadelphia, PA

### **Critical Care**

43. The Impact of a Pharmacist-Managed Acid Suppression Program on Inappropriate Therapy in the Intensive Care Unit.

Dr. Mitchell S. Buckley, Pharm.D., FASHP, FCCM, BCPS<sup>1</sup>, Dr. Andrew Park, Pharm.D.<sup>1</sup>, Dr. Clint Anderson, Pharm.D., BCPS<sup>2</sup>, Dr. Jeffrey Barletta, Pharm.D.<sup>3</sup>, Dr. Dale Bikin, Pharm.D.<sup>2</sup>, Dr. Laura Wicks, Pharm.D.<sup>2</sup>, Dr. Cheryl O'Malley, M.D.<sup>4</sup>, Dr. Richard Gerkin Jr., M.D., M.S., FACP, FACMT<sup>5</sup>, Dr. Sandra L. Kane-Gill, PharmD, MSc, FCCM, FCCP<sup>6</sup>; (1)Department of Pharmacy, Banner Good Samaritan Medical Center, Phoenix, AZ; (2)Pharmacy, Banner Good Samaritan Medical Center, Phoenix, AZ; (3)Department of Pharmacy Practice, Midwestern University, College of Pharmacy-Glendale, Glendale, AZ; (4)Internal Medicine, Banner Good Samaritan Medical Center, Phoenix, AZ; (5)Graduate Medical Education Research, Banner Good Samaritan Medical Center, Phoenix, AZ; (6)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

# **Education/Training**

63. Different educational methods for health system pharmacists with diverse backgrounds. Shannon Holt, PharmD, BCPS, Roseann Richards, PharmD, Lynn Eschenbacher, PharmD, MBA, FASHP; Department of Pharmacy, WakeMed Health & Hospitals, Raleigh, NC

### **Emergency Medicine**

65E. Impact of clinical pharmacists on initiation of post-intubation analgesia in the emergency department.

*Dr. Lamies Abuakar, PharmD, BCPS*, Dr. Erin Robey-Gavin, PharmD, BCPS; Mercy Hospital and Medical Center, Chicago, IL

69. Is CURES the cure? A prospective, observational study of the impact of a priori knowledge of controlled substance history.

*Dr. Justin Warren, Pharm.D.*<sup>1</sup>, Dr. Roneet Lev, M.D.<sup>2</sup>, Dr. Lisa Mueller, Pharm.D.<sup>1</sup>, Dr. Yelena Atlasevich, Pharm.D.<sup>1</sup>, Dr. Harminder Sikand, Pharm.D.<sup>1</sup>; (1)Department of Pharmacy, Scripps Mercy Hospital, San Diego, CA; (2)Department of Emergency Medicine, Scripps Mercy Hospital, San Diego, CA

# **Endocrinology**

72E. Canagliflozin reduces serum uric acid in patients with type 2 diabetes mellitus. Dr. Michael Davies, PhD¹, Dr. Angelina Trujillo, MD FACE², Dr. Ujjwala Vijapurkar, PhD³, Chandrasekharrao V. Damaraju, PhD⁴, Dr. Gary Meininger, MD³; (1)Diabetes - Medical Affairs, Janssen Scientific Affairs, LLC., Raritan, NJ; (2)Janssen Scientific Affairs, LLC.; (3)Janssen Research & Development, LLC; (4)Janssen Research & Development, LLC, Raritan, NJ

# **Family Medicine**

85. A Qualitative Investigation Describing Human Resource Infrastructure Roles and Responsibilities in Practice-based Research Networks.

Brandon Patterson, PharmD, PhD<sup>1</sup>, Shanrae'l Stoner, PharmD (candidate)<sup>2</sup>, William Douecette, PhD, Barcey Levy, MD, PhD, Dr. Barry Carter, Pharm.D.<sup>4</sup>, Julie Urmie, PhD, Mary Schroeder, PhD; (1)Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, Philadelphia, PA; (2)IA; (3)University of Iowa College of Pharmacy, Iowa City, IA

86E. Impact of Cough and the Common Cold on Productivity and Quality of Life: Results From the US Attitudes of Consumers Toward Health, Cough, and Cold Survey.

Dr. Peter Dicpinigaitis, MD<sup>1</sup>, Dr. Ronald Eccles, DSc<sup>2</sup>, Dr. Michael Blaiss, MD<sup>3</sup>, Dr. Mark Wingertzahn, PhD<sup>4</sup>; (1)Division of Pulmonary Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY; (2)Common Cold Centre, Cardiff School of Biosciences, Cardiff, Wales, United Kingdom; (3)Allergy Immunotherapy, Merck & Co., Roswell, GA; (4)Global Clinical Development, Pfizer Consumer Health, Madison, NJ

88E. Improving Health For At-Risk Rural Patients (IHARP): Identification and Resolution of Medication Related Problems.

Dr. Leticia R. Moczygemba, PharmD, PhD<sup>1</sup>, Dr. Heidi Wengerd, PharmD<sup>2</sup>, Dr. Andrea L. Pierce, PharmD<sup>1</sup>, Dr. Michael Czar, PhD, RPh<sup>2</sup>, Dr. Tanvi Patil, PharmD<sup>2</sup>, Dr. Nikisa Blevins, PharmD<sup>2</sup>, Dr. Karen Williams, PharmD<sup>2</sup>, Dr. Courtney Dickerson, PharmD<sup>2</sup>, Dr. Kelley Mills, PharmD<sup>2</sup>, Dr. William Lee, BPharm, MPA<sup>2</sup>, Dr. Gary R. Matzke, PharmD<sup>1</sup>; (1)Department of Pharmacotherapy and Outcomes Sciences, Virginia Commonwealth University School of Pharmacy, Richmond, VA; (2)Carilion New River Valley Medical Center

### Gastroenterology

92. Fluoroquinolone Sequential Therapy for Helicobacter pylori.

Sheila Wilhelm, Pharm.D., BCPS<sup>1</sup>, Anela Mihaescu, Pharm.D. Candidate<sup>2</sup>, Pramodini Kale-Pradhan, Pharm.D.<sup>3</sup>; (1)Department of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy & Health Sciences and Harper University Hospital, Detroit, MI; (2)Department of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy & Health Sciences, Detroit, MI; (3)Department of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy & Health Sciences and St. John Hospital and Medical Center, Detroit, MI

93. Omega-3 long-chain polyunsaturated fatty acids enhance tight junction formation in intestinal epithealial cells.

*Emma M. Tillman, Pharm.D., Ph.D.*<sup>1</sup>, Peihong Guan, B.S.<sup>1</sup>, Dr. Radhakrishna Rao, Ph.D.<sup>2</sup>; (1)University of Tennessee Health Science Center College of Pharmacy, Memphis, TN; (2)The University of Tennessee Health Science Center

96F. The Impact of a Clinical Pharmacist-Managed Acid Suppression Program on Inappropriate Therapy in General Ward Patients.

*Dr. Mitchell S. Buckley, Pharm.D., FASHP, FCCM, BCPS*<sup>1</sup>, Dr. Clint Anderson, Pharm.D., BCPS<sup>2</sup>, Dr. Andrew Park, Pharm.D.<sup>1</sup>, Dr. Jeffrey Barletta, Pharm.D.<sup>3</sup>, Dr. Dale Bikin, Pharm.D.<sup>2</sup>, Dr. Richard Gerkin Jr., M.D., M.S.,

FACP, FACMT<sup>4</sup>, Dr. Laura Wicks, Pharm.D.<sup>2</sup>, Dr. Cheryl O'Malley, M.D.<sup>5</sup>, Dr. Sandra L. Kane-Gill, PharmD, MSc, FCCM, FCCP<sup>6</sup>; (1)Department of Pharmacy, Banner Good Samaritan Medical Center, Phoenix, AZ; (2)Pharmacy, Banner Good Samaritan Medical Center, Phoenix, AZ; (3)Department of Pharmacy Practice, Midwestern University, College of Pharmacy-Glendale, Glendale, AZ; (4)Graduate Medical Education Research, Banner Good Samaritan Medical Center, Phoenix, AZ; (5)Internal Medicine, Banner Good Samaritan Medical Center, Phoenix, AZ; (6)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

### **Health Services Research**

102E. Health-Related Quality of Life in Persons with Apparent Treatment-Resistant Hypertension Taking at Least Four Antihypertensives.

Steven Smith, PharmD, MPH<sup>1</sup>, Vahram Ghushchyan, PhD<sup>2</sup>, Anne Libby, PhD<sup>3</sup>; (1)Department of Pharmacotherapy & Translational Research; Department of Community Health & Family Medicine, University of Florida, Gainesville, FL; (2)American University of Armenia, Armenia; (3)Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO

### **HIV/AIDS**

109. Topical application of tenofovir DF nanoparticles prevents HIV-1 vaginal transmission in humanized-BLT mice.

*Dr. Christopher Destache, Pharm. D.*<sup>1</sup>, Dr. Abhijit Date, Ph. D.<sup>1</sup>, Zhe Yuan, M. S.<sup>2</sup>, Guobin Kang, B.S.<sup>2</sup>, Dr. Wuxun Lu, Ph. D.<sup>2</sup>, Dr. For Yue Tso, Ph. D.<sup>2</sup>, Dr. Charles Wood, Ph. D.<sup>2</sup>, Dr. Qingsheng Li, Ph. D.<sup>2</sup>; (1)Department of Pharmacy Practice, Creighton University School of Pharmacy & Health Professions, Omaha, NE; (2)Center for Virology, University of Nebraska-Lincoln, Lincoln, NE

#### **Infectious Diseases**

112. Impact of antibiotic choice on pneumonia readmission rates.

*Dr. Alice Hemenway, PharmD*<sup>1</sup>, Michael Naretta, MS<sup>2</sup>; (1)Department of Pharmacy Practice, UIC College of Pharmacy/Rockford Memorial Hospital, Rockford, IL; (2)Michigan State University

113. Utilization of a clinical bedside scoring system (ATLAS) to determine treatment regimens in patients with Clostridium difficile-associated diarrhea.

Jonathan Cho, Pharm.D., Rajendra Sharma, M.D., John Armitstead, MS, RPh, FASHP, Sandy Estrada, Pharm.D., BCPS, AQ-ID; Lee Memorial Health System, Fort Myers & Cape Coral, FL

- 114. Beta-lactam monotherapy versus beta-lactam plus an aminoglycoside or ciprofloxacin in sepsis. *Mary Lenefsky, PharmD*<sup>1</sup>, Bryan D. Lizza, PharmD, BCPS<sup>1</sup>, Erik Rachwalski, PharmD<sup>1</sup>, John S. Esterly, Pharm.D.<sup>2</sup>; (1)Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL; (2)Chicago State University College of Pharmacy, Chicago, IL
- 115. The Impact of Pharmacy-Based Immunization Regulations on Influenza Vaccination Rates. *Dr. Kevin McConeghy, Pharm.D.*<sup>1</sup>, Dr. Coady Wing, Ph.D.<sup>2</sup>; (1)Dept. of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, IL; (2)Dept. of Health Policy and Administration, University of Illinois at Chicago School of Public Health, Chicago, IL
- 118. Correlation of cefpodoxime susceptibility with cefazolin and cefuroxime among urinary tract isolates.

*Dr. David Bookstaver, Pharm.D.*, Dr. Christopher Bland, Pharm.D.; Department of Pharmacy, Eisenhower Army Medical Center, Fort Gordon, GA

119. Evaluation of Alternative Alerts as a Tool for Antimicrobial Stewardship.

Brett Van Rossum, PharmD; Department of Pharmacy, Froedtert and the Medical College of Wisconsin, Milwaukee, WI

120. Evaluation of a screening process for the early detection of sepsis: A pilot program. *Jonathan D. Edwards, Pharm, D*, Dr. Nicholas Massie, Pharm.D., Dr. Jonathan Spry, Pharm.D.; Department of Pharmacy, Huntsville Hospital, Huntsville, AL

121F. Missed Opportunities for Congenital Syphilis Prevention in Baltimore City. *Stephanie Atueyi, PharmD, MPH*<sup>1</sup>, Glen Olthoff, MHA, MA<sup>2</sup>, Evelyn Awah, Pharm.D, BCPS<sup>3</sup>; (1)College of Public Health and Health Profession, University of Florida; (2)STD/HIV Prevention Program, Baltimore City Health Department, Baltimore, MD; (3)Department of Pharmacy, Johns Hopkins Hospital, Baltimore, MD

122E. Role of Rta3 in fluconazole resistance in Candida albicans.

Sarah G. Whaley, Pharm.D., Katherine S. Barker, Ph.D., P. David Rogers, Pharm.D., Ph.D.; University of Tennessee College of Pharmacy, Memphis, TN

### **Medication Safety**

133. Association Between Topiramate Use and Serum Bicarbonate Levels in a Veteran Population. Dr. Anna Sciegienka, PharmD, Dr. Tami Argo, MS, BA, PharmD, BCPP, *Dr. Matthew Cantrell, PharmD, BCPS*, Dr. Bruce Alexander, PharmD, BS; Iowa City Veterans Affairs Health Care System, Iowa City, IA

# Nephrology

139. Using the MedLit-D tool to assess medication label literacy in patients on hemodialysis. *Dr. Soo Min Jang, PharmD*<sup>1</sup>, Dr. Wendy Parker, Ph.D.<sup>2</sup>, Dr. Amy Barton Pai, BS, Pharm.D., BCPS, FASN, FCCP<sup>3</sup>, Ms. Kristine Ferreira, PharmD Candidate<sup>4</sup>, Dr. Katie Cardone, Pharm.D., BCACP, FNKF<sup>3</sup>; (1)Dept. of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY; (2)Dept. of Basic and Social Sciences, Albany College of Pharmacy and Health Sciences, 12208, NY; (3)Dept. of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY; (4)Albany College of Pharmacy and Health Sciences

#### Other

152F. Description and Validation of the Disease Interaction Scoring Tool (DIST) for an Electronic Health Record (EHR) Integrated Drug Knowledgebase.

Dr. Jeff Bubp, PharmD¹, Dr. Joan Kapusnik-Uner, PharmD², Dr. Brian Hoberman, MD, MBA³, Dr. Harrison Wright, MD⁴, Dr. Emanuel Kwahk, PharmD⁵, Dr. Karl A. Matuszewski, PharmD, MS⁶; (1)Clinical Editorial, Disease Decision Support Group, First Databank, Inc., South San Francisco, CA; (2)Clinical Editorial, First Databank, Inc., South San Francisco, CA; (3)Department of Medicine, Kaiser Permanente, San Francisco, CA; (4)Family Medicine Department, Kaiser Permanente, Rohnert Park, CA; (5)School of Pharmacy, Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA; (6)First Databank, Inc., South San Francisco, CA

#### **Pediatrics**

155. Restricted Use of Repeat Doses of Surfactant after the Prophylactic Dose Does NOT Increase the Risk of BPD or Death in Preterm Infants.

*Varsha Bhatt-Mehta, MS, (CRDSA), Pharm.D., FCCP*<sup>1</sup>, Dr. Subrata Sarkar, MD<sup>2</sup>; (1)University of Michigan, Ann Arbor, MI; (2)Neonatal Perinatal Medicine, University of Michigan, Ann Arbor, MI

#### **Pharmacoeconomics/Outcomes**

159F. Pharmacogenetic-guided selection of oral anticoagulants: A cost-effectiveness analysis. *Dr. Joyce You, PharmD, BCPS*; School of Pharmacy, The Chinese University of Hong Kong, Hong Kong

162. Completeness of Medication Part D Claims in the Atherosclerosis Risk in Communities (ARIC) Study: Influence of of Generic Drug Discount Programs and Veterans Affairs Drug Benefit. *Emily M. Thudium, PharmD*<sup>1</sup>, Lei Zhou, MSPH<sup>2</sup>, Khalid A. Alburikan, PharmD, BCPS<sup>3</sup>, Sally C. Stearns, PhD<sup>4</sup>, Eliza S. Daubert, PharmD<sup>3</sup>, Jo E. Rodgers, PharmD, FCCP, BCPS (AQ Cardiology)<sup>5</sup>; (1)Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, NC; (2)Gillings School of Pulic Health, University of North Carolina at Chapel Hill; (3)Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; (4)Health Policy and Management, UNC Gillings School of Public Health, Chapel Hill, NC; (5)Division of Pharmacotherapy and Experimental Therapeutics, Eshelman Scool of Pharmacy, University of North Carolina, Chapel Hill, NC

# **Pharmacoepidemiology**

164. Dosing decision of ACE inhibitors and angiotensin II receptor blockers among the elderly after acute myocardial infarction: the role of patient age and risk factors.

Sandra Hanna, PharmD Candidate, Izabela Annis, MS, Gang Fang, PharmD, MS, PhD; Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, NC

### **Pharmacogenomics/Pharmacogenetics**

165. Genome-wide association study of fluoroquinolone-induced tendonitis. *Dr. Jason Karnes, PharmD, PhD*, Dr. Jonathan Mosley, MD, PhD, Mr. Christian Shaffer, BS, Dr. Erica Bowton, PhD, Dr. Jessica Delaney, MD, Dr. Sara Van Driest, MD, PhD, Dr. Peter Weeke, MD, Dr. Quinn Wells, PharmD, MD, Dr. Joshua Denny, MD, Dr. Dan Roden, MD; Department of Medicine, Vanderbilt University, Nashville, TN

167E. Increasing the Tamoxifen Dose in CYP2D6 Intermediate Metabolizers Increases Toxicity. *Daniel Hertz, PharmD PhD*<sup>1</sup>, Anna Snavely, PhD<sup>2</sup>, James Evans, MD, PhD<sup>2</sup>, Joseph Ibrahim, PhD<sup>2</sup>, Christine Walko, PharmD<sup>3</sup>, Steven Anderson, MD<sup>4</sup>, Karen Weck, MD<sup>5</sup>, Peter Rubin, MD<sup>6</sup>, Oludamilola Olajide, MD<sup>7</sup>, Susan Moore, MD<sup>7</sup>, Rachel Raab, MD<sup>8</sup>, Daniel Carrizosa, MD<sup>9</sup>, Steven Corso, MD<sup>10</sup>, Garry Schwartz, MD<sup>9</sup>, Jeffrey Peppercorn, MD<sup>11</sup>, Mark Graham, MD<sup>12</sup>, Sean Canale, MD<sup>13</sup>, Howard McLeod, PharmD<sup>3</sup>, Lisa Carey, MD<sup>2</sup>, William Irvin Jr., MD<sup>14</sup>; (1)Department of Clinical Social and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, MI; (2)University of North Carolina at Chapel Hill; (3)Moffitt Cancer Center; (4)Laboratory Corporation of America; (5)School of Medicine, University of North Carolina, Chapel Hill, NC; (6)Moses Cone Regional Cancer Center; (7)Rex Hematology Oncology Associates;

(8)Brody School of Medicine at East Carolina University; (9)Carolinas Medical Center Hematology-Oncology Associates; (10)Palmetto Hematology Oncology; (11)Duke Cancer Institute; (12)Waverly Hematology Oncology; (13)Carolina Breast Care Specialists; (14)Bon Secours Cancer Institute

# Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery

172. Pharmacokinetics, Safety, and Tolerability of Single and Multiple-doses of Pinocembrin Injection Administered Intravenously in Healthy Subjects.

Ms. Guoying Cao, MD; Beijing Hospital, China

175. Lack of Correlation between PK and Changes in Pulmonary Artery Systolic Pressure in Healthy Volunteers Following Administration of the HIF-Prolyl Hydroxylase Inhibitor, GSK1278863.

Dr. Laura Demopoulos, MD, Dr. Eric Olson, PhD; Heart Failure DPU, GlaxoSmithKline, King of Prussia, PA

176E. Crushing ticagrelor tablets accelerates exposure compared with intact tablets.

Dr. Renli Teng, PhD, Dr. Glenn Carlson, MD, Dr. Judith Hsia, MD; AstraZenecaLP, Wilmington, DE

177. Assessing Real World Dose Adjustment in Patients Switching from Intravenous Immunoglobulin (IGIV) Therapy to Subcutaneous Immunoglobulin (IGSC) 20%.

Xiaolan Ye, PhD<sup>1</sup>, Yan Xiong, MS<sup>2</sup>, Josephine Li-McLeod, PhD<sup>2</sup>; (1)Baxter HealthCare, Deerfield, IL; (2)Baxter HealthCare, Westlake Village, CA

178. Comparing estimated glomerular filtration rates based on serum creatinine versus serum cystatin C and effect on renal dosing of medications.

*Marissa Trester, Pharm.D.*, Lorraine Wang, Pharm.D., Shirley Chao, Pharm.D., Daniel Maddix, Pharm.D.; Pharmacy Services, San Francisco Veterans Affairs Medical Center, San Francisco, CA

# **Pulmonary**

181. A proof of concept study to evaluate use of aerosolized 13C-urea to detect urease-producing bacteria in lungs of cystic fibrosis patients.

Hengameh Raissy, Pharm.D.<sup>1</sup>, Theresa Heynekamp, MD<sup>2</sup>, Lea Davies, MD<sup>3</sup>, Michelle Harkins, MD<sup>4</sup>; (1)Pediatrics, University of New Mexico, Albuquerque, NM; (2)Internal Medicine, University of New Mexico, Albuquerque, NM; (3)Depratemtn of Pedicatrics, University of New Mexico, Albuquerque, NM; (4)Department of internal medicine, University of New Mexico, Albuquerque, NM

182. A dose-escalating study to evaluate safety of aerolized 13C-urea to detect urease-producing bacteria in lungs of cystic fibrosis patients.

Hengameh Raissy, Pharm.D.<sup>1</sup>, Theresa Heynekamp, MD<sup>2</sup>, Lea Davies, MD<sup>3</sup>, Michelle Harkins, MD<sup>4</sup>; (1)Pediatrics, University of New Mexico, Albuquerque, NM; (2)Internal Medicine, University of New Mexico, Albuquerque, NM; (3)Depratemtn of Pedicatrics, University of New Mexico, Albuquerque, NM; (4)Department of internal medicine, University of New Mexico, Albuquerque, NM

# Transplant/Immunology

189. Risk Prediction Model for Late Posttransplant Anemia in Renal Allograft Recipients. *Dr. Jae Wook Yang, PharmD, PhD, BCPS*<sup>1</sup>, Dr. Tariq Shah, MD<sup>2</sup>, Dr. Robert Naraghi, MD<sup>2</sup>, David I. Min, MS, Pharm.D.<sup>3</sup>; (1)Department of Pharmacy Practice, School of Pharmacy, West Coast University, Los Angeles, CA; (2)Mendez National Institute of Transplantation, Los Angeles, CA; (3)School of Pharmacy, Western University of Health Sciences, Pomona, CA

190E. Efficacy, Safety and Tolerability of Recombinant Human Hyaluronidase-Facilitated Subcutaneous infusion of immunoglobulin in Adult Subjects with Primary Immunodeficiency Enrolled in a Phase 3 Study.

Mark Stein, MD<sup>1</sup>, Richard Wasserman, MD, Ph.D<sup>2</sup>, Isaac Melamed, MD<sup>3</sup>, Arye Rubinstein, MD, Ph.D<sup>4</sup>, Jennifer Puck, MD<sup>5</sup>, Sudhir Gupta, MD, Ph.D, MACP<sup>6</sup>, Werner Engl, MD<sup>7</sup>, Heinz Leibl, Ph.D<sup>7</sup>, Barbara McCoy, MD<sup>7</sup>, Leman Yel, MD<sup>8</sup>, *Richard Schiff, MD, Ph.D*<sup>8</sup>; (1)Allergy Associates of the Palm Beaches, North Palm Beach, FL; (2)DallasAllergyImmunology, Dallas, TX; (3)IMMUNOe Health Centers, Centennial, CO; (4)Albert Einstein College of Medicine and Montefiore Hospital, Bronx, NY; (5)University of California, San Francisco, San Francisco, CA; (6)University of California, Irvine, Irvine, CA; (7)Baxter Healthcare, Vienna, Austria; (8)Baxter Healthcare, Westlake Village, CA

194. Impact of Basiliximab Administration Time on Patient Outcomes in Cardiopulmonary Bypass Dependent Lung Transplant.

Angela T. Logan, PharmD, BCPS<sup>1</sup>, Esther Liu, PharmD<sup>1</sup>, Tarik Haddad, MD FCCP<sup>2</sup>; (1)Department of Pharmacy, Tampa General Hospital, Tampa, FL; (2)New Lung Associates, Tampa, FL

198. Tacrolimus trough concentrations increase in intestinal transplant recipients during episodes of acute cellular rejection.

Alicia Lichvar, PharmD<sup>1</sup>, Heather J. Johnson, PharmD, BCPS<sup>2</sup>, David Deen, PharmD, BCPS, BCNSP<sup>3</sup>, Jennifer Bonner, PharmD, PhD<sup>4</sup>, Geoffrey Bond, MD<sup>5</sup>, Guilherme Costa, MD, FACS<sup>5</sup>, Kareem Abu-Elmagd, MD, PhD, FACS<sup>6</sup>, Raman Venkataramanan, PhD<sup>7</sup>; (1)Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (3)Department of Pharmacy, Memorial University Medical Center, Savannah, GA; (4)Northern Institute for Cancer Research at Newcastle University; (5)Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; (6)Center for Gut Rehabilitation and Transplantation, Cleveland Clinic, Clevland, OH; (7)Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA

199. Efficacy of once weekly dapsone dosing for PCP prophylaxis post-transplantation. *Rickey Evans, PharmD*, Timothy Clifford, PharmD, BCPS, Ann Fugit, PharmD, BCPS; Department of Pharmacy Services, University of Kentucky Healthcare, Lexington, KY

# Urology

201. Clinical Trial of Alfuzosin Stone Expulsion Therapy for Distal Uretral Calcui: Efficacy and Patient Outcome Evaluation.

Mrs. Nouran El Said, B Pharm<sup>1</sup>, Dr. Lamia El Wakeel, PhD<sup>2</sup>, Dr. Khaled Kamal, MD<sup>3</sup>; (1)Department of Pharmacy Practice & Clinical Pharmacy, Faculty of Pharmaceutical Sciences& Pharmaceutical Industries, Fututre University in Egypt, Cairo, Egypt; (2)Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; (3)Faculty of Medicine, Ain Shams University, Cairo, Egypt

#### **CLINICAL PHARMACY FORUM**

These abstracts describe the delivery, development, justification, or documentation of an innovative clinical pharmacy service; they may be descriptive only and need not contain an evaluative component.

# **ADR/Drug Interactions**

203E. Comparison of new-onset gout incidence in adults prescribed chlorthalidone versus hydrochlorothiazide.

Dr. Liza Wilson, PharmD<sup>1</sup>, Vahram Ghushchyan, PhD<sup>2</sup>, Richard Allen, M.S.<sup>3</sup>, Kavita V. Nair, PhD<sup>4</sup>, Joseph Saseen, Pharm.D.<sup>5</sup>; (1)School of Medicine, University of Missouri - Kansas City, Kansas City, MO; (2)American University of Armenia, Armenia; (3)Peak Statistical Services, Evergreen, CO; (4)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO; (5)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

#### **Adult Medicine**

207F. UPMC St. Margaret COPD Free Medication Program: Impact on 30-Day Readmission Rate and Pharmacoeconomic Utility.

*Dr. Jennie Broders, PharmD, BCPS*<sup>1</sup>, Dr. Priscilla Ko, PharmD<sup>2</sup>, Frank D'Amico, PhD<sup>3</sup>; (1)UPMC St. Margaret Family Medicine Residency Program, UPMC St. Margaret, Pittsburgh, PA; (2)UPMC St. Margaret, Pittsburgh, PA; (3)UPMC St. Margaret

## **Ambulatory Care**

208. Pharmacist recommendations for novel oral anticoagulant transition in patients with a low time in therapeutic range on warfarin.

Peggy Tilbury, PharmD, Emily Hays, PharmD, Melissa Duke, PharmD; Intermountain Healthcare

209. Innovations in Interdisciplinary Diabetes Management.

*Kelsey Buckley, Pharm.D., BCACP*; Department of Pharmacy Practice, Midwestern University College of Pharmacy-Glendale, Glendale, AZ

215. Virtual pharmacy senior care population management in ambulatory care setting. Dr. Candace Minter, PharmD<sup>1</sup>, *Dr. Jessie Lish, PharmD, BCPS*<sup>2</sup>, Dr. Brad Myers, PharmD, MBA, BCPS<sup>3</sup>, Mrs. Mary Morin, RN, MSN, BSN, NEA-BC, RN-BC<sup>4</sup>, Dr. Daniel Dickinson, MD, MPH<sup>5</sup>; (1)Pharmacy Administration, Sentara Medical Group, Norfolk, VA; (2)Ambulatory Clinical Pharmacy, Sentara Healthcare System-Sentara Medical Group, Norfolk, VA; (3)Department of Pharmacy, Sentara Healthcare System, Norfolk, VA; (4)Sentara Healthcare System-Sentara Medical Group, Norfolk, VA; (5)Sentara Medical Group, Norfolk, VA

217. Retrospective Analysis of Billing and Reimbursement at a Stand-Alone Medication Therapy Management Clinic.

*Keri Hager, Pharm.D.*<sup>1</sup>, Rena Gosser, Pharm.D.<sup>2</sup>; (1)Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota College of Pharmacy, Duluth, MN; (2)University of Wisconsin Hospital & Clinics, Madison, WI

219. Description of collaboration between primary care clinical pharmacy and dermatology. *Stephanie Cho, PharmD, BCPS*, Sara Klockars, PharmD, BCPS; Kaiser Permanente Colorado, CO

#### Cardiovascular

224. Clinical Outcomes of a Post-Discharge Heart Failure Medication Reconciliation Clinic. *Dr. Stephanie Ogorzaly, Pharm.D.*<sup>1</sup>, Ms. Julie Gee, R.N., M.S.N, C.N.P.<sup>2</sup>, Dr. Robert Wenzell, Pharm.D.<sup>1</sup>, Dr. Christopher Burant, Ph.D.<sup>3</sup>, Dr. Jose Ortiz, M.D.<sup>2</sup>, Dr. Sherry Milfred-LaForest, Pharm.D.<sup>1</sup>; (1)Department of Pharmacy, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH; (2)Department of Cardiology, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH; (3)Geriatric Research, Education & Clinical Center (GRECC), Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH

225. Characterization of a Pharmacist-Managed Heart Failure Medication Titration Clinic: Patient Population, Outcomes, and Barriers to Titration.

*Dr. Shubha Bhat, PharmD*<sup>1</sup>, Dr. Mayank Kansal, MD<sup>2</sup>, Dr. Thomas Stamos, MD<sup>2</sup>, Dr. George Kondos, MD<sup>2</sup>, Dr. Vicki L. Groo, PharmD<sup>1</sup>; (1)Department of Pharmacy Practice, University of Illinois at Chicago; (2)Department of Medicine, University of Illinois at Chicago

#### **Clinical Administration**

227. Evaluation of a therapeutic substitution of albuterol/ipratropium combination inhalers to nebulizers at an academic medical center.

*Dr. Steven Loborec, PharmD*, Dr. Shawn Johnson, PharmD, MPH, BCPS, BCNSP, Dr. Ellen Keating, PharmD, MS; Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH

#### **Critical Care**

232F. Improved survival after Advanced Cardiovascular Life Support: outcomes associated with the implementation of pharmacist documentation during in-hospital cardiac arrest events. *Dr. Mojdeh Heavner, PharmD*<sup>1</sup>, Ms. Jessica Nuzzo, MPH<sup>2</sup>, Dr. Jason Heavner, MD<sup>3</sup>, Ms. Frances Veiga, BS<sup>2</sup>, Dr. David Pritchard, PharmD<sup>1</sup>, Dr. Renee Fekieta, PhD<sup>2</sup>, Dr. Ginger Morris, PharmD<sup>1</sup>, Ms. Melani Semlow, RN, MSN<sup>4</sup>, Dr. Grace Jenq, MD<sup>5</sup>, Ms. Marie Devlin, RN<sup>4</sup>, Ms. Kathleen Testa, RN, MPH<sup>2</sup>, Dr. William Crede, MD<sup>2</sup>; (1)Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT; (2)Quality Improvement Support Services, Yale-New Haven Hospital, New Haven, CT; (3)Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT; (4)Yale-New Haven Hospital, New Haven, CT; (5)Department of Medicine, Yale School of Medicine, New Haven, CT

234E. Assessment of clinical outcomes in pneumonia patients treated with enteral antibiotics in the surgical intensive care unit.

Kathryn Elofson, PharmD<sup>1</sup>, Rachel Forbes, MD, MBA<sup>2</sup>, *Anthony Gerlach, PharmD, BCPS, FCCM*<sup>3</sup>; (1)Huntsman Cancer Hospital, University of Utah Hospitals & Clinics; (2)Vanderbilt University Medical Center; (3)The Ohio State University Wexner Medical Center

### **Education/Training**

235. Pre-operative screening of patients at a university-affiliated periodontal clinic carried out by pharmacy students trained in the performance and interpretation of findings from a physical assessment of vital signs.

*Dr. Christine Leong, B.Sc., B.Sc.(Pharm), Pharm.D.*<sup>1</sup>, Dr. Anastasia Cholakis, D.M.D.<sup>2</sup>, Mr. Christopher Louizos, B.Sc.(Pharm), Dr. Neal Davies, BSc.(Pharm), Ph.D, R.Ph.<sup>1</sup>, Dr. Douglas Brothwell, D.M.D. D.D.P.H. M.Sc.<sup>2</sup>; (1)Faculty of Pharmacy, University of Manitoba, Winnipeg, MB, Canada; (2)Faculty of Dentistry, University of Manitoba, Winnipeg, MB, Canada

238. Implementing a layered learning model in a small, community hospital: economic and patient satisfaction outcomes.

Mate Soric, Pharm.D., BCPS<sup>1</sup>, Jason Glowczewski, Pharm.D., MBA<sup>2</sup>, Rachael Lerman, Pharm.D., BCPS<sup>1</sup>; (1)Department of Pharmacy, University Hospitals Geauga Medical Center, Chardon, OH; (2)University Hospitals Health System, Shaker Heights, OH

239E. Evaluation of a student interprofessional team disclosure of a medication error to a patient. Dr. Kelly Ragucci, PharmD<sup>1</sup>, Sarah P. Shrader, Pharm.D., BCPS<sup>2</sup>; (1)Department of Clinical Sciences and Outcomes Sciences, South Carolina College of Pharmacy, Charleston, SC; (2)University of Kansas School of Pharmacy, KS

240. Evaluation of the Interprofessional Teaching Clinic model: Preparing medical, nursing, and pharmacy students to collaborate.

James Kleoppel, PharmD<sup>1</sup>, Cari Chestnut, PharmD Candidate<sup>1</sup>, Jana Zaudke, MD<sup>2</sup>, Sarah P. Shrader, Pharm.D., BCPS<sup>3</sup>; (1)University of Kansas School of Pharmacy; (2)University of Kansas Medical Center; (3)University of Kansas School of Pharmacy, KS

# **Emergency Medicine**

244. Emergency medicine clinical pharmacist's impact on the medication reconciliation process. *Elaine DePrang, PharmD, BCPS*<sup>1</sup>, Dr. Arun Mathews, MD<sup>2</sup>; (1)Trauma Department, Medical Center Hospital, Odessa, TX; (2)Medical Center Hospital, Odesa, TX

246. Analgesic response to intramuscular ketorolac in the obese patient population in the Emergency Department.

Megan Van Berkel, Pharm.D., BCPS<sup>1</sup>, Brittany Jonap, Pharm.D., BCPS<sup>2</sup>, Lori Davis, EMT-P<sup>3</sup>, *Ana Negrete, Pharm.D., BCPS*<sup>1</sup>; (1)Pharmacy Department, Methodist University Hospital, Memphis, TN; (2)Department of Pharmacy, Methodist University Hospital; (3)Emergency Department, Methodist University Hospital

### **Endocrinology**

247. Clinical effect of sitagliptin on Hemoglobin A1c after sleeve gastrectomy. *Mr. Christopher M. Bland, PharmD, BCPS*<sup>1</sup>, Dr. Christos Hatzigeorgiou, MD<sup>2</sup>, David A. Bookstaver, Pharm.D.<sup>3</sup>, Lori B. Sweeney, MD<sup>4</sup>, Mrs. Marguerite de Haseth, Pharm.D.<sup>5</sup>; (1)Department of Clinical Pharmacy, Eisenhower Army Medical Center, Fort Gordon, GA; (2)Department of Internal Medicine, Eisenhower Army Medical Center, Fort Gordon, GA, GA; (3)Eisenhower Army Medical Center, Fort Gordon, GA; (4)Department of Internal Medicine; Division of Endocrinology and Metabolism, Virginia Commonwealth University, Richmond, VA; (5)Medical University of South Carolina, Charleston, SC

### **Geriatrics**

252. Prevalence and description of potentially inappropriate medications found in a community-based rural-dwelling elderly population.

Shara Elrod, PharmD<sup>1</sup>, Leigh Johnson, PhD<sup>2</sup>, Ashley Toale, PharmD<sup>3</sup>; (1)Department of Pharmacotherapy, University of North Texas System College of Pharmacy, Fort Worth, TX; (2)Department of Internal Medicine, University of North Texas Health Science Center, Fort Worth; (3)Department of Pharmacotherapy, University of North Texas System College of Pharmacy, Fort Worth

### **HIV/AIDS**

259E. Simplification of PI/RTV+FTC/TDF to E/C/F/TDF Maintains HIV Suppression and is Well-Tolerated. Dr. William Towner, MD¹, Dr. Edwin DeJesus, MD², Dr. U. Fritz Bredeek, MD, PhD³, Dr. Jose Arribas, MD⁴, Dr. Jeffery Olson, PharmD⁵, Ramin Ebrahimi, MS⁶, Dr. David Piontkowsky, JD, MD³; (1)Infectious Disease, Kaiser Permanente Southern California, Los Angeles, CA; (2)Orlando Immunology Center, Orlando, FL; (3)Metropolis Medical, San Francisco, CA; (4)Hospital La Paz, Madrid, Spain; (5)Managed Care / Government Account Medical Sciences, Gilead Sciences, New York, NY; (6)Biostatistics, Gilead Sciences, Foster City, CA; (7)Medical Affairs HIV, Gilead Sciences, Foster City, CA

260. Establishing a Clinical Pharmacy Practice in an Integrated-Service HIV Outpatient Clinic. Dr. Andrea Pallotta, PharmD, BCPS, AAHIVP<sup>1</sup>, Sherrell Lipscomb, MEd, LSW<sup>2</sup>, Dr. Marisa Tungsiripat, MD<sup>2</sup>; (1)Department of Pharmacy, Cleveland Clinic, Cleveland, OH; (2)Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH

264. HIV Telemedicine in the Correctional Setting.

Dr. Melissa E. Badowski, PharmD; University of Illinois at Chicago College of Pharmacy, Chicago, IL

#### **Infectious Diseases**

269. The impact of liver dysfunction on therapeutic outcomes in patients receiving vancomycin therapy. Sweta Patel, PharmD (c)<sup>1</sup>, *Luigi Brunetti, PharmD, MPH*<sup>2</sup>, Stuart Vigdor, RPh<sup>2</sup>, Ronald Nahass, MD, MHCM<sup>2</sup>; (1)Rutgers, The State University of New Jersey, Ernest Mario School of Pharmacy, Piscataway, NJ; (2)Robert Wood Johnson University Hospital Somerset, Somerville, NJ

270E. Evaluation of the In vitro Potency of Itraconazole, Voriconazole, and Posaconazole and Resistance in Aspergillus Isolates from the United States.

*Nathan Wiederhold, PharmD*, Annette Fothergill, MS, Dora McCarthy, MT, Carmita Sanders, MT, Deanna Sutton, PhD; School of Medicine, Department of Pathology, UT Health Science Center at San Antonio, San Antonio, TX

271. Evaluation of steady state vancomycin trough concentrations post implementation of various dosing regimens.

Matthew Gibson, PharmD, Kari Mount, PharmD, BCPS, Eric Wenzler, PharmD, BCPS, Jordan Lundberg, PharmD, Karri Bauer, PharmD, BCPS; The Ohio State University Wexner Medical Center

272. Implement colistin loading dose to improve the efficacy and safety.

Ms. Judy Jui-Fen Chang, Pharm.D., B.S., C.D.E., Ms. Lan-Hsi Lin, B.S., Meng-Ting Hsu, M.S., Ms. Chia-Shan Tsai, M.S., Ms. Tong-Ling Chien, B.S., Ms. Wuan-Jin Leu, M.S.; Department of Pharmacy, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan

### **Medication Safety**

273E. Consumer medication information: a reliable source of information on grapefruit juice interactions?.

*Dr. Donna Huynh, PharmD, MA*, Dr. Linh Van, PharmD, Dr. James Breen, PharmD, Dr. Nicholas Ratto, PharmD; Consumer Drug Information Group, First Databank, Inc. (FDB), South San Francisco, CA

274. Pharmacist Discharge Medication Reconciliation on an Advanced Heart Failure Service Prevents Medication Errors.

Dr. Christina Doligalski, PharmD, BCPS; Department of Pharmacy, Tampa General Hospital, Tampa, FL

275. Pharmacist Medication Reconciliation in an Advanced Heart Failure Clinic Prevents Medication Errors.

Christina T. Doligalski, PharmD, BCPS; Department of Pharmacy, Tampa General Hospital, Tampa, FL

#### Other

280. Improvements in Medication History Outcomes with Student Pharmacists.

Dr. Aubrie Rafferty, PharmD, BCPS<sup>1</sup>, *Elizabeth Michalets, Pharm.D, BCPS, FCCP*<sup>2</sup>, Dr. Barbara Kostic, PharmD, BCPS, CPP<sup>1</sup>; (1)Department of Pharmacy, Mission Hospital, Asheville, NC; (2)Mission Health System and UNC Eshelman School of Pharmacy, Asheville, NC

### Pain Management/Analgesia

283E. Efficacy and Safety of a Pharmacist-Managed Patient Controlled Analgesia Service.

Katrina Mcgonigal, PharmD<sup>1</sup>, Brian Raveau, BS<sup>2</sup>, Christopher A. Giuliano, PharmD<sup>2</sup>, *Jeff Hurren, PharmD*<sup>1</sup>; (1)Department of Pharmacy Services, St John Hospital & Medical Center, Detroit, MI; (2)Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI

284. Impact of the Perioperative Use of Intravenous Acetaminophen in Patients Undergoing Intraabdominal and Breast Reconstruction Surgery.

*Dr. Kimberly Tallian, PharmD, BCPP, FASHP, FCCP, FCSHP*<sup>1</sup>, Dr. Jonathan Schmidt, PharmD<sup>2</sup>; (1)School of Pharmacy, Keck Graduate Institute, Claremont, CA; (2)Department of Pharmacy, Scripps Memorial Hospital, La Jolla, La Jolla, CA

### **Pharmacogenomics/Pharmacogenetics**

287. Barriers to implementing pharmacogenetic testing in an urban population. *Yee Ming Lee, Pharm.D.*<sup>1</sup>, Katarzyna Drozda, Pharm.D.<sup>1</sup>, Jinger Hoop, MD<sup>2</sup>, Julio D. Duarte, Pharm.D., Ph.D<sup>1</sup>, Edith A. Nutescu, Pharm.D, MS<sup>1</sup>, Larisa Cavallari, Pharm.D.<sup>3</sup>; (1)University of Illinois at Chicago, College of Pharmacy, Chicago, IL; (2)Department of Psychiatry, University of Illinois at Chicago, Chicago, IL; (3)Department of Pharmacotherapy and Translational Research, University of Florida, FL

### **Psychiatry**

289. Placement of a clinical psychiatric pharmacist within a primary care clinic. Dr. Richard Silvia, Pharm.D., BCPP; Department of Pharmacy Practice, MCPHS University, Boston, MA

# Transplant/Immunology

290. Evaluation of Antifungal Prophylaxis Duration in Kidney Transplant Recipients. *Christina Guerra, Pharm.D., BCPS*, Eric M. Tichy, Pharm.D., BCPS, Teena Sam, Pharm.D., BCPS, William S. Asch, MD, Richard N. Formica Jr., MD, Sanjay Kulkarni, MD, FACS; Yale-New Haven Hospital, CT

291. Hepatitis C Medication Management and Reconciliation Errors: Impact of a Clinical Pharmacist. *Dr. Aileen Chi, Pharm.D.*<sup>1</sup>, Dr. David Quan, Pharm.D.<sup>1</sup>, Dr. Norah Terrault, MD<sup>2</sup>; (1)Department of Pharmaceutical Services, UCSF Medical Center, San Francisco, CA; (2)Division of Gastroenterology, UCSF Medical Center, San Francisco, CA

#### STUDENT SUBMISSIONS

These papers describe original research by students in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, and pharmacogenomics.

# **ADR/Drug Interactions**

323. Comparison of three adverse drug reaction pharmacovigilance instruments to determine the causality of published case reports.

Nan Wang, PharmD Candidate, BS<sup>1</sup>, Erin Resetar, PharmD Candidate, BS<sup>1</sup>, Lindsey Rihtarchik, PharmD Candidate, BS<sup>1</sup>, Ms. Maria Felton, BS, PharmD (pending)<sup>2</sup>, Sandra Kane-Gill, Pharm.D., MS, FCCM, FCCP<sup>1</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)School of Pharmacy, University of Pittsburgh, PA

324. Assessing the quality of published adverse drug reaction case reports using the Naranjo Criteria. *Ms. Maria Felton, BS, PharmD (pending)*<sup>1</sup>, Lindsey Rihtarchik, PharmD Candidate, BS<sup>2</sup>, Erin Resetar, PharmD Candidate, BS<sup>2</sup>, Nan Wang, PharmD Candidate, BS<sup>2</sup>, Sandra Kane-Gill, Pharm.D., MS, FCCM, FCCP<sup>2</sup>; (1)School of Pharmacy, University of Pittsburgh, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

326. Study based on FDA report of Metronidazole-Kaolin interaction.

Dr. Fadilah Aleanizy, PhD; king saud universiy, riyadh

327. Impact of Co-administration of Bortezomib and Vitamin C on Anti-myeloma Activity and Peripheral Neuropathy in Multiple Myeloma Patients.

*Mrs. Hyun Eun Chu, B.S.*<sup>1</sup>, Mr. Myeong Gyu Kim, B.S.<sup>1</sup>, Jung Mi Oh, Professor<sup>2</sup>; (1)College of Pharmacy, Seoul National University, Seoul, South Korea; (2)College of Pharmacy, Seoul National University, Soeul, South Korea

### **Adult Medicine**

328. A retrospective cohort analysis of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with chronic liver disease.

Kaitlyn J. Moorehead, BS, Scott W. Mueller, PharmD; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO

329. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.

Sonalie Patel, Pharm.D. Candidate 2015<sup>1</sup>, Katie Buehler, PharmD<sup>1</sup>, Anastasia Armbruster, Pharm.D., BCPS<sup>1</sup>, Michael Daly, PharmD, MSCl<sup>2</sup>; (1)St. Louis College of Pharmacy, Saint Louis, MO; (2)Saint Louis University Hospital, Saint Louis, MO

# **Ambulatory Care**

330. Evaluation of Pharmacy Health Literacy Assessment in Outpatient Pharmacies. *Erik Henricksen, PharmD Candidate 2016*, Karissa Kim, Pharmd, CACP, BCPS; James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH

#### Cardiovascular

331. Impact of Pharmacists' Interventions on Readmission Rate within 12 months after Discharge in Heart Failure Patients: a meta-analysis.

*Ms. Dannielle Brown, Pharmacy Student*, Dr. David Ombengi, PharmD, Dr. Hua Ling, PharmD; Department of Pharmacy Practice, Hampton University, Hampton, VA

### **Critical Care**

335. Risk factors for discharge on a new antipsychotic medication after admission to an intensive care unit.

Rachel A. Curtis, PharmD Candidate<sup>1</sup>, *Leslie A. Hamilton, PharmD, BCPS*<sup>2</sup>, Camellia R. Davis, PharmD Candidate<sup>1</sup>, Victoria W. Reynolds, PharmD Candidate<sup>1</sup>, Leslie N. Smith, PharmD<sup>3</sup>, Grayson K. Peek, PharmD<sup>4</sup>, A. Shaun Rowe, PharmD, BCPS<sup>1</sup>; (1)Department of Clinical Pharmacy, University of Tennessee Health Science Center, College of Pharmacy, Knoxville, TN; (2)The University of Tennessee Health Science Center, College of Pharmacy, Knoxville, TN; (3)Department of Pharmacy, Methodist University Hospital, Memphis, TN; (4)Department of Pharmacy, Duke University Hospital, Durham, NC

336. Descriptive analysis of prescriber acceptance of pharmacist recommended interventions in a critical care unit at a community hospital.

*Mr. Timothy Egbuka, Doctor of Pharmacy Candidate 2015*, Ms. YoonJung Lee, Doctor of Pharmacy Candidate 2015, Dr. Jordan Carmack, Pharm D., Dr. William Cusick, Pharm D., Dr. Lana Gettman, Pharm D.; Pharmacy Practice, Harding University College of Pharmacy, Searcy, AR

337. Association between vancomycin dosage and acute kidney injury, pharmacodynamic target attainment and clinical response in critically ill surgical patients.

*Elizabeth Lakatos, Doctor of Pharmacy*, Christopher Droege, Doctor of Pharmacy, Neil Ernst, Doctor of Pharmacy, Jon Hicks, Doctor of Pharmacy, Eric Mueller, Doctor of Pharmacy; University of Cincinnati Medical Center

338. Safety and efficacy of insulin glargine versus insulin infusions in hyperglycemic intensive care unit (ICU) patients.

Benjamin Pullinger, PharmD Candidate, Marissa Casagrande, PharmD Candidate, Kristen Schmerbeck, PharmD Candidate, Dr. Christina Rose, PharmD, BCPS; Temple University School of Pharmacy, Philadelphia, PA

339F. Characterization of delirium in a medical ICU that emphasizes frequent delirium screening at a tertiary, academic medical center.

Nicholas Farina, BS<sup>1</sup>, Kevin Ordons, BS<sup>1</sup>, Rachel Filiaggi, BS<sup>1</sup>, Melissa Shook, BS<sup>1</sup>, Csevolak Marissa, BS<sup>1</sup>, Sandra Kane-Gill, Pharm.D., MS, FCCM, FCCP<sup>2</sup>, Pamela L. Smithburger, Pharm.D., BCPS<sup>3</sup>, Ryan Rivosecchi, PharmD<sup>4</sup>; (1)School of Pharmacy, University of Pittsburgh, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (3)University of Pittsburgh Medical Center, Pittsburgh, PA; (4)University of Pittsburgh Medical Center - Presbyterian Hospital, Pittsburgh, PA

# **Drug Information**

340. Understanding of Off-Label Drug Use Among Pharmacy Students. Lendy Le, PharmD Candidate<sup>1</sup>, Tonna Farinha, PharmD<sup>2</sup>, Micheline Goldwire, PharmD, MSc, BS<sup>3</sup>; (1)School Of Pharmacy, Regis University School of Pharmacy, Denver, CO; (2)Regis, Regis University School of Pharmacy, Denver, CO; (3)School of Pharmacy, Regis University, Denver, CO

### **Education/Training**

342. Effect of part-time employment on academic performance while completing the Pharm.D. curriculum.

Ms. Jenna Andrzejewski, PharmD candidate<sup>1</sup>, Ms. Lindsey Zawierucha, PharmD candidate, Ms. Mary Wilkie, MBA, PharmD candidate<sup>1</sup>, Dr. Stephanie Brian, PharmD, BCPS<sup>1</sup>, Dr. Nicole Cieri, PharmD, BCPS<sup>1</sup>; (1)D'Youville College School of Pharmacy

343. Evaluation of a pre-pharmacy student mentoring program at the University of Cincinnati James L. Winkle College of Pharmacy.

Caitlin M. Delabar, Pharm.D. Candidate 2016, Tyler A. Vest, Pharm.D. Candidate 2016, Karissa Y. Kim, Pharm.D., CACP, BCPS; University of Cincinnati James L. Winkle College of Pharmacy, Cincinnati, OH

# **Emergency Medicine**

352. Efficacy and safety of intravenous procainamide for the treatment of recent-onset atrial fibrillation. *Nicolle Steel, PharmD Candidate*, Stephen Rolfe, PharmD, BCPS; University of New England, College of Pharmacy, Portland, ME

### **Family Medicine**

356. Estimated Statin Treatment Changes in Adopting ACC/AHA Guidelines in an Employer Based Primary Care Clinic.

Marisa B Schauerhamer, PharmD<sup>1</sup>, Holly Gurgle, PharmD, BCACP, CDE<sup>2</sup>, Peter Weir, MD, MPH<sup>2</sup>, Carrie McAdam-Marx, RPh, MS, PhD<sup>3</sup>; (1)Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, UT; (2)ARUP Family Health Clinic, ARUP Laboratories, Salt Lake City, UT; (3)Department of Pharmacotherapy & Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT

#### **Geriatrics**

357. Change in anticholinergic use over a ten-year period in community dwelling elders. *Maria Felton, BS, PharmD (pending)*<sup>1</sup>, Zachary A. Marcum, PharmD, BCPS<sup>2</sup>, Dr. Subashan Perera, PhD<sup>3</sup>, Joseph Hanlon, PharmD, MS<sup>4</sup>; (1)School of Pharmacy, University of Pittsburgh, Pittsburgh, PA;

(2)University of Pittsburgh, PA; (3)Diviision of Geriatrics, UPITT School of Medicine, Pittsburgh, PA; (4)Division of Geriatrics, UPITT School of Medicine, Pittsburgh, PA

358. Impact of the inclusion of creatinine clearance on antibiotic order forms in a long-term care facility. *Elizabeth Sagan, Pharm.D. Candidate*, Stephanie Ring, Pharm.D., Amber McLendon, Pharm.D.; College of Pharmacy and Health Sciences, Campbell University, Buies Creek, NC

# **Hematology/Anticoagulation**

361F. Evaluating current recommended dose of enoxaparin in renally impaired and morbidly obese patients by monitoring anti-factor Xa levels.

*Mr. Austin Ballew, B.S.*, Dr. Young Lee, Pharm.D., Dr. Jose Vega, Pharm.D., Dr. Hanh-Nhi Duong, Pharm.D.; Texas Tech University Health Science Center School of Pharmacy, Abilene, TX

362. Review of anticoagulant and antiplatelet therapy in an outpatient setting.

*Kyle Carlisle, AA; PharmD candidate*<sup>1</sup>, Katherine Vogel Anderson, Pharm.D., BCACP<sup>2</sup>; (1)Colleges of Pharmacy and Medicine, University of Florida, Gainesville, FL; (2)Department of Pharmacotherapy and Translational Research, Division of General Internal Medicine, University of Florida Colleges of Pharmacy and Medicine, Gainesville, FL

### **HIV/AIDS**

365. Moringa oleifera in HIV/AIDS patients.

Ms. Zaritza Cajigas, 2015 Pharm D Candidate<sup>1</sup>, Ms. Angelica Borrero, Pharm D Candidate<sup>2</sup>, Ms. Gladiany Ramos, Pharm D Candidate<sup>2</sup>; (1)School of Pharmacy, Nova Southeastern University Puerto Rico Campus, San Juan, PR; (2)School of Pharmacy, Nova Southeastern University Puerto Rico Campus, San Juan

366. Incidence of antiretroviral prescribing errors among admitted patients.

Josh Beavers, PharmD Candidate<sup>1</sup>, Lisa Blanchette, PharmD, BCPS<sup>2</sup>, Rachel Justus, PharmD, BCPS<sup>2</sup>; (1)Wingate University School of Pharmacy, Winston-Salem, NC; (2)Department of Pharmacy, Novant Health Presbyterian Medical Center, Charlotte, NC

368. Evaluation of viral suppression in re-incarcerated HIV prisoners followed in a telemedicine clinic. *Jeffrey Neal, PharmD Candidate*<sup>1</sup>, Dr. Mahesh Patel, MD<sup>2</sup>, Dr. Jeremy Young, MD, MPH<sup>2</sup>, Pyrai Vaughn, MA<sup>2</sup>, Dr. Melissa E. Badowski, PharmD<sup>3</sup>; (1)Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy; (2)University of Illinois at Chicago, College of Pharmacy, Chicago, IL

369. The rise in polypharmacy and prescribed medications among persons living with HIV (PLWH). *Ms. Heather Moore, B.S., Pharm.D. Candidate*<sup>1</sup>, Dr. Christine Oramasionwu, Pharm.D., Ph.D., BCPS<sup>1</sup>, Mr. Lu Mao, M.S., Ph.D. Candidate<sup>2</sup>; (1)UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; (2)UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC

### **Infectious Diseases**

372. The Role of Mdr1 in Azole Resistance in Clinical Isolates of Candida parapsilosis. *Kayihura Manigaba, BS*, Elizabeth Berkov, MS, P. David Rogers, Pharm.D., Ph.D.; University of Tennessee College of Pharmacy, Memphis, TN 374. Inappropriate Spectrum of Empiric Antibiotics in Critically-III Patients with Pseudomonas aeruginosa Infections.

*Mr. Philip Leong, PharmD Candidate*<sup>1</sup>, Dr. Jacob Beyer, Doctor of Pharmacy<sup>2</sup>, Scott W. Mueller, PharmD<sup>3</sup>; (1)School of Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO; (2)University of Colorado Hospital, Denver, CO; (3)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO

375. Health disparities by race among hospitalized adults with *Clostridium difficile* infections in the United States, 2001 to 2010.

Jacqueline Argamany, Pharm.D. Student<sup>1</sup>, Kelly Reveles, Pharm.D., Ph.D.<sup>2</sup>; (1)College of Pharmacy, The University of Texas at Austin, San Antonio, TX; (2)College of Pharmacy, The University of Texas at Austin, TX

376. Clinical efficacy of linezolid in the treatment of urinary tract infections caused by vancomycin-resistant enterococci species: a retrospective study.

Rebecca Kim, Pharm.D. Candidate Class of 2015<sup>1</sup>, Pouria Khan, Pharm.D. Candidate Class of 2015<sup>2</sup>, Farzad Hatanian, Pharm.D. Candidate Class of 2015<sup>1</sup>, Diane Rhee, Pharm.D.<sup>1</sup>; (1)Roseman University of Health Sciences; (2)College of Pharmacy, Roseman University of Health Sciences, Henderson, NV

378. Declining Incidence of Diabetic Foot Infections among Hospitalized Adults in the U.S. from 1996 to 2010 Encore.

Bryson Duhon, Pharm.D., Elizabeth Hand, Pharm.D., *Crystal Howell, n/a*, Kelly Reveles, Pharm.D., Ph.D.; College of Pharmacy, The University of Texas at Austin, TX

379F. Ceftaroline and daptomycin combinations demonstrates synergistic and bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) from a patient who failed daptomycin. *Iffat Shafiq, PharmD Candidate*<sup>1</sup>, Kari Mergenhagen, PharmD<sup>2</sup>, Sarah Spitznogle, PharmD Candidate<sup>1</sup>, Zackery Bulman, PharmD Candidate<sup>1</sup>, John Diep, PharmD Candidate<sup>1</sup>, Alan Lesse, MD<sup>2</sup>, Brian T. Tsuji, PharmD<sup>1</sup>; (1)University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY; (2)VA Western New York Healthcare System, Buffalo, NY

380F. Polymyxin combinations to combat polymyxin resistant KPC-producing *Klebsiella pneumoniae*. *John Diep, PharmD Candidate*<sup>1</sup>, Cely S. Abboud, MD<sup>2</sup>, Brenda Yu, PharmD Candidate<sup>1</sup>, David Jacobs, PharmD<sup>1</sup>, Patricia N. Holden, BS<sup>1</sup>, Alan Forrest, PharmD<sup>1</sup>, Brian T. Tsuji, PharmD<sup>1</sup>, Gauri Rao, PharmD<sup>1</sup>; (1)University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY; (2)Infection Control Department, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

382. Antifungal therapeutic drug monitoring in hematopoietic stem cell transplant patients: real world comparison of the time to therapeutic levels of posaconazole and voriconazole. *Sarah S. Kim, Pharm.D. candidate*, Stacey Chung, Pharm.D. candidate, Lovitta Jiwanmall, Pharm.D. candidate, Connor Luczak, Pharm.D. candidate, Dr. Peggy Carver, Pharm.D.; College of Pharmacy, University of Michigan, Ann Arbor, MI

383. Antibiotic polytherapy against multidrug-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae infections: case series and systematic review.

Heeyoung Byun, PharmD Candidate<sup>1</sup>, Cely S. Abboud, MD<sup>2</sup>, John Diep, PharmD Candidate<sup>1</sup>, Brenda Yu,

PharmD Candidate<sup>1</sup>, Gauri G. Rao, PharmD<sup>1</sup>, David M. Jacobs, PharmD<sup>1</sup>; (1)University at Buffalo School of

Pharmacy and Pharmaceutical Sciences, Buffalo, NY; (2)Infection Control Department, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

384. Evaluation of a Vancomycin Dosing Protocol in Adult Patients in a Multicenter, Community Hospital Setting.

*Mr. Brian Fox, Pharm.D. Candidate 2015*, Dr. Lisa Costanigro, Pharm.D., BCPS; Poudre Valley Hospital, University of Colorado Health System - North, Fort Collins, CO

## **Medication Safety**

387. Pharmacists' active interventions as a means to identify medication misadventure in pediatrics. *Ms. Hesty Ramadaniati, M.Clin.Pharm*, Ya Lee, PhD., Jeff Hughes, PhD., School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University, Perth, Australia

## Nephrology

390. Analysis of drug related problems and evaluation of clinical pharmacist's intervention on chronic kidney disease patients.

Ms. Seung Hee Han, B.S., Ms. Ga Hyeon Lee, M.S., Ms. Na Young Han, M.S., Mrs. Jung Mi Oh, Pharm. D; Clinical Pharmacy, College of Pharmacy, Seoul National University, Seoul, South Korea

## **Neurology**

391. Assessing the incidence of inappropriate medication use in hospitalized patients with Parkinson's disease.

*Nicholas Cox, Pharm.D. Candidate*<sup>1</sup>, Jessica Louie, Pharm.D.<sup>1</sup>, Rishi Deka, Ph.D. Candidate, M.S.<sup>2</sup>, Rodolfo Savica, M.D., M.S.<sup>3</sup>, Benson Sederholm, Pharm.D., BCPS<sup>1</sup>; (1)Department of Pharmacy Services, University of Utah Hospitals and Clinics, Salt Lake City, UT; (2)Department of Pharmacotherapy, University of Utah, Salt Lake City, UT; (3)Department of Neurology, University of Utah Hospitals and Clinics, Salt Lake City, UT

### **Nutrition**

392. Prevention of bile acid-induced apoptosis with omega-3 long-chain polyunsaturated fatty acids in a cholestatic liver disease model.

*Timothy J. Howze, Pharm.D. Candidate*<sup>1</sup>, Brent McGlaughlin, B.S. Candidate<sup>2</sup>, Peihong Guan, B.S.<sup>1</sup>, Richard A. Helms, Pharm.D.<sup>1</sup>, Emma M. Tillman, Pharm.D., Ph.D.<sup>1</sup>; (1)University of Tennessee Health Science Center College of Pharmacy, Memphis, TN; (2)Christian Brothers University, Memphis, TN

### Oncology

394. Improvement in Access to Oral Chemotherapeutic Agents at a Tertiary Care Hospital through the use of Medication Assistance Pharmacy Specialists.

*Mr. Taylor White, BS, PharmD Candidate*<sup>1</sup>, Dr. Tippu Khan, PharmD, BCOP, CPP<sup>2</sup>, Dr. Henry Burgess, PharmD, MBA<sup>2</sup>, Dr. Lindsey Poppe, PharmD, MS, BCPS<sup>2</sup>, Dr. Benyam Muluneh, PharmD, BCOP, CPP<sup>2</sup>; (1)University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC; (2)UNC Healthcare, Chapel Hill, NC

395. Screening for Hepatitis B Virus (HBV) prior to rituximab chemotherapy.

Alyson N. Leonard, PharmD Candidate, Bryan L. Love, PharmD, BCPS, LeAnn B. Norris, PharmD, BCPS, BCOP; South Carolina College of Pharmacy, Columbia, SC

397. Significance of Clinical Pharmacists' Drug-related Interventions for Patients with Hematologic Malignancies.

Mrs. Hyun Eun Chu, B.S.<sup>1</sup>, Chae Reen Jeong, M.S.<sup>2</sup>, Mr. Myeong Gyu Kim, B.S.<sup>1</sup>, Jae Hyun Kim, B.S.<sup>3</sup>, Ms. Na Young Han, M.S.<sup>4</sup>, Mrs. Jung Mi Oh, Pharm. D<sup>4</sup>; (1)College of Pharmacy, Seoul National University, Seoul, South Korea; (2)2Department of Pharmacy, Asan Medical Center, SEOUL, South Korea; (3)College of Pharmacy, Seoul National University, SEOUL; (4)Clinical Pharmacy, College of Pharmacy, Seoul National University, Seoul, South Korea

#### Other

400. Evaluation of Botulinum Toxin Utilization in the Oregon Medicaid Program.

*Dr. Andrew Sowles, PharmD*<sup>1</sup>, Mr. Lincoln Alexander, B.S.<sup>1</sup>, Dr. Megan Herink, PharmD<sup>1</sup>, Kathleen Ketchum, M.P.A. H.A<sup>2</sup>; (1)College of Pharmacy, Oregon State University/Oregon Health & Science University, Portland, OR; (2)College of Pharmacy, Oregon State University/Oregon Health & Science University, Corvallis, OR

402. Development and Validation of Patient Decision Aid for Depressed Patients.

*Ms. Heba Alshammari, Bachelor*<sup>1</sup>, Ms. Kholoud Alaamer, Bachelor<sup>1</sup>, Ms. Mashael Albassam, Bachelor<sup>1</sup>, Dr. Khalaf Aljumah, MSc<sup>2</sup>; (1)School of Pharmacy, King Saud University, Riyadh; (2)Ministry Of Health, Riyadh

403. The IMPACT of Decision Aid on Depressed Patients' Involvement in Shared Decision Making: A PILOT Randomized Controlled Double-Blinded Study.

*Ms. Heba Alshammari, Bachelor*<sup>1</sup>, Ms. Kholoud Alaamer, Bachelor<sup>1</sup>, Ms. Mashael Albassam, Bachelor<sup>1</sup>, Mr. Khalaf Aljumah, MSc<sup>2</sup>; (1)School of Pharmacy, King Saud University, Riyadh; (2)Ministry Of Health, Riyadh

#### **Pediatrics**

410. Evaluation of preoperative antimicrobial prophylaxis in select neonatal intensive care unit surgeries. *Ashley Byrne, Pharm.D. Candidate 2015*<sup>1</sup>, Mary Petrea Cober, Pharm.D., BCNSP<sup>2</sup>; (1)College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH; (2)Akron Children's Hospital, Akron, OH

412. Kidney Function, Vancomycin Dosing and Achievement of Therapeutic Troughs: A Pilot Observational Study in Pediatric Oncology Patients.

Alexandra Chambers, PharmD Candidate<sup>1</sup>, Thomas D. Nolin, PharmD, PhD<sup>2</sup>, Dr. Denise Schiff, PharmD<sup>3</sup>; (1)University of Pittsburgh School of Pharmacy, PA; (2)University of Pittsburgh, Pittsburgh, PA; (3)Hematology/Oncology, Children's Hospital of Pittsburgh of UPMC

### **Pharmacoeconomics/Outcomes**

413. Utilizing clinical pharmacist specialists to address access to care barriers in the type 2 diabetes (T2DM) veteran population.

Ryan Hadley, PharmD Candidate, Laura Pedromo, PharmD Candidate, Nidhu Baby, PharmD Candidate, Cole Kildow, Pharm.D., MSHA, BCACP, CDE, Megan Stapleton, Pharm.D., BCACP, CDE, Krystal Edwards, Pharm.D., FCCP, BCPS; Texas Tech UHSC School of Pharmacy, Dallas, TX

414. Development and validation of a multidimensional scale "CLEO" for evaluating potential significance of pharmacist interventions.

Ms. Thi-Ha Vo, Pharm.D.<sup>1</sup>, Ms. Claire Catoire, Pharm.D.<sup>1</sup>, Mr. Bruno Charpiat, Pharm.D.<sup>2</sup>, Mr. Michel Juste, Pharm.D.<sup>2</sup>, Mr. Renaud Roubille, Pharm.D.<sup>2</sup>, Mr. Francois-Xavier Rose, Pharm.D.<sup>2</sup>, Mr. Jean-Luc Bosson, M.D.<sup>1</sup>, Ms. Ornella Conort, Pharm.D.<sup>2</sup>, Mr. Benoit Allenet, Pharm.D.<sup>2</sup>, Mr. Pierrick Bedouch, Pharm.D.<sup>2</sup>; (1)Univ. Grenoble Alpes/CNRS/TIMC-IMAG UMR 5525/ThEMAS & Grenoble University Hospital, Grenoble, France; (2)"Standardization and Valorization of Clinical Pharmacy Activities" working group of the French Society of Clinical Pharmacy (SFPC), France

# **Pharmacogenomics/Pharmacogenetics**

415F. Impact of a pharmacist guided pharmacogenetics service on prediction of warfarin stable dose. *Daniel Gratie, PharmD Candidate*<sup>1</sup>, Cheng Wendy, MS<sup>1</sup>, Katarzyna Drozda, Pharm.D.<sup>2</sup>, Julio Duarte, Pharm.D., Ph.D<sup>1</sup>, James Lee, PharmD<sup>1</sup>, William L. Galanter, MD, PhD<sup>1</sup>, John Garofallo, PharmD<sup>1</sup>, Jerry A. Krishnan, MD, PhD<sup>3</sup>, Larisa Cavallari, PharmD<sup>1</sup>, Edith Nutescu, PharmD, MS<sup>1</sup>; (1)University of Illinois at Chicago College of Pharmacy, Chicago, IL; (2)University of Illinois at Chicago, College of Pharmacy, Chicago, IL; (3)University of Illinois at Chicago, Pulmonary, Critical Care, and Sleep Medicine, Chicago, IL

# **Substance Abuse/Toxicology**

420. The serotonin-2 receptor modulator, (-)-trans-PAT, decreases voluntary ethanol consumption in rats. *Mr. Joseph Ladd, 2015 Pharm.D. Candidate*; Department of Pharmacodynamics, University of Florida College of Pharmacy, Gainesville, FL

### **Transplant/Immunology**

422. Fenofibrate impact on graft function after renal transplantation - fact or fiction. Ms. Kripa Patel, BA<sup>1</sup>, Ms. Melissa Moriarty, BS<sup>1</sup>, Maya Campara, PharmD<sup>2</sup>, Sanjeev Akkina, MD<sup>2</sup>; (1)Pharmacy Practice, University of Illinois at Chicago, Chicago, IL; (2)University of Illinois Hospital and Health Sciences System, Chicago, IL

424. A comparison of cumulative rabbit antithymocyte globulin dose and clinical outcomes in obese kidney transplant patients.

Benjamin Duhart Jr., M.S., Pharm.D.<sup>1</sup>, *Dagny Ulrich, Ph.D.*<sup>2</sup>, Vinaya Rao, M.D.<sup>3</sup>; (1)Pharmacy, University of Tennessee Health Science Center/ Methodist University Hospital, Memphis, TN; (2)Pharmacy, University of Tennessee Health Science Center, Memphis, TN; (3)Transplant Nephrology, University of Tennessee Health Science Center/ Methodist University Hospital Transplant Institute, Memphis, TN

#### **LATE BREAKERS**

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

### **Education/Training**

429. A comparison of the entry characteristics of the highest and lowest performers on the North American pharmacist licensure examination.

Connie H. Yoon, Pharm.D., Jill Morgan, PharmD, Bhavi Patel, PharmD Candidate, Cherokee Layson-Wolf, PharmD, Lisa Lebovitz, JD; University of Maryland School of Pharmacy, Baltimore, MD

# **Medication Safety**

437. Pharmacist facilitated admission and discharge medication reconciliation reduces medication errors. *Julie L. Cunningham, PharmD*<sup>1</sup>, Dr. Lance Oyen, PharmD<sup>2</sup>, Dr. Jenna Lovely, PharmD<sup>3</sup>, Dr. Christopher McCoy, MD<sup>4</sup>, Dr. David Larson, MD<sup>5</sup>, Ms. Diane Foss, RN<sup>6</sup>; (1)Department of Hospital Pharmacy Services; College of Medicine Mayo Clinic, Mayo Clinic, Rochester, MN; (2)Department of Hospital Pharmacy Services; College of Medicine Mayo Clinic, Mayo Medical Center, Rochester, MN; (3)Department of Information Systems, Mayo Medical Center, Rochester, MN; (4)Department of Hospital Internal Medicine, College of Medicine Mayo Clinic, Mayo Medical Center, Rochester, MN; (5)Department of Colon and Rectal Surgery, College of Medicine Mayo Clinic, Mayo Medical Center, Rochester, MN; (6)Department of Nursing, Mayo Medical center, Rochester, MN

# Pharmacogenomics/Pharmacogenetics

442F. Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical outcome and drug response.

Dr. David DeRemer, Pharm.D. BCOP<sup>1</sup>, Dr. Megan Hartranft, Pharm.D. BCPS<sup>2</sup>, Dr. Ashis Mondal, Ph.D.<sup>3</sup>, Dr. Ravindra Kolhe, M.D. Ph.D<sup>4</sup>, Dr. Bradley Phillips, Pharm.D. BCPS FCPP<sup>5</sup>; (1)Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Augusta, GA; (2)Department of Pharmacy Practice, Rosalind Franklin College of Pharmacy, Chicago, IL; (3)Department of Pathology, Georgia Regents University, Augusta, GA; (4)Department of Pathology, Georgia Regents University, Georgia Regents Cancer Center, Augusta, GA; (5)Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Athens, GA